Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: An open-label, naturalistic study

Journal of Clinical Psychiatry

Volumn 70, Issue 7, 2009, Pages 1054-1056

  Maron, Eduard ^a,b   Eller, Triin ^b   Vasar, Veiko ^b   Nutt, David J ^c  

^a North Estonia Medical Centre   (Estonia)

^b UNIVERSITY OF TARTU   (Estonia)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; ZOLPIDEM; ZOPICLONE;

ADULT; ANXIETY DISORDER; BECK DEPRESSION INVENTORY; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; INSOMNIA; LETTER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; MUSCLE TWITCH; OPEN STUDY; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BUPROPION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 68049120350     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08l04477     Document Type: Letter

References (17)

1. Mischoulon D, Nierenberg AA, Kizilbash L, et al. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry 2000;45(5):476-481
2. Zisook S, Rush AJ, Haight BR, et al. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006;59(3):203-210
3. Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6(4):159-166
4. Sheehan DV, Lecrubier Y, Sheehan KH, et al. Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
5. Montgomery SA, Asberg MC. A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
6. Guy W. EDCEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976;218-222
7. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
8. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
9. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002;47(2):174-180
10. Papakostas GI, Worthington JJ 3rd, Iosifescu DV, et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 2006;23(3):178-181
11. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354(12):1243-1252
12. Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 2004;65(3):337-340
13. Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006;67(6):865-873
14. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006;60(12):1350-1355
15. Nutt DJ, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007;21(5):461-471
16. Höschl C, Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother 2008;8(4):537-552
17. Wade A, Despiegel N, Heldbo Reines E. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry 2006;18(2):83-89